

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

PDL BIOPHARMA, INC.
Form SC 13G/A
February 12, 2010

Page 1 of 11 Pages

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities exchange Act of 1934

(AMENDMENT NO.1) *

PDL BIOPHARMA INC

(NAME OF ISSUER)

COM

(TITLE OF CLASS OF SECURITIES)

69329Y104

(CUSIP NUMBER)

December 31, 2009

(Date of event which requires filing of this Statement)

NOTE: A MAJORITY OF THE SHARES REPORTED IN THIS SCHEDULE 13G ARE HELD BY UNAFFILIATED THIRD-PARTY CLIENT ACCOUNTS MANAGED BY ALLIANCEBERNSTEIN L.P., AS INVESTMENT ADVISER. (ALLIANCEBERNSTEIN L.P. IS A MAJORITY-OWNED SUBSIDIARY OF AXA FINANCIAL, INC.)

this Schedule is filed:

- X Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(CONTINUED ON FOLLOWING PAGE(S))

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

	No. of Shares Subtotals -----
The Mutuelles AXA, as a group	0
AXA	0
AXA Entity or Entities	
Common acquired solely for investment	
AXA Investment Managers UK Ltd	526,705
AXA Rosenberg Investment	60,351
AXA Financial, Inc.	0
Subsidiaries:	
AllianceBernstein L.P.	
acquired solely for investment	
purposes on behalf of client	
discretionary investment advisory	
accounts:	
Common Stock	227,412
	227,412

Total	814,468
	=====

Each of the Mutuelles AXA, as a group, and AXA expressly declares that the filing of this Schedule 13G shall not be construed as an admission that it is, for purposes of Section 13(d) of the Exchange Act, the beneficial owner of any securities covered by this Schedule 13G.

Each of the above subsidiaries of AXA Financial, Inc. operates under independent management and makes independent decisions.

(b) Percent of Class: 0.7%
=====

Page 9 of 11 Pages

ITEM 4. Ownership as of

(CONT.)

(c) Deemed Voting Power and Disposition Power:

	(i)	(ii)	(iii)	(iv)
	Deemed	Deemed	Deemed	Deemed
	to have	to have	to have	to have
	Sole Power	Shared Power	Sole Power	Shared
Power	to Vote	to Vote	to Dispose	to Dispose
	or to	or to	or to	or to
	Direct	Direct	Direct the	Direct the

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

	the Vote	the Vote	Disposition	Disposition
	-----	-----	-----	-----
The Mutuelles AXA, AXA	0	0	0	0
AXA Entity or Entities:				
AXA Investment Managers UK Ltd	526,705	0	526,705	0
AXA Rosenberg Investment Management LLC	60,351	0	60,351	0
AXA Financial, Inc.	0	0	0	0
Subsidiaries:				

AllianceBernstein	227,412	0	227,412	0
	-----	-----	-----	-----
	814,468	0	814,468	0
	=====	=====	=====	=====

Each of the above subsidiaries of AXA Financial, Inc. operates under independent management and makes independent voting and investment decisions.

Page 10 of 11 Pages

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, (X)

Item 6. Ownership of More than Five Percent on behalf of Another Person. N/A

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reporting on by the Parent Holding Company:

This Schedule 13G is being filed by AXA Financial, Inc.; AXA, which owns AXA Financial, Inc.; and the Mutuelles AXA, which as a group control AXA:

(X) in the Mutuelles AXAs' capacity, as a group, acting as a parent holding company with respect to the holdings of the following AXA entity or entities:

(X) in AXA's capacity as a parent holding company with respect to the holdings of the following AXA entity or entities:

AXA Investment Managers UK Ltd

AXA Rosenberg Investment Management LLC

(X) in AXA Financial, Inc.'s capacity as a parent holding company

with respect to the holdings of the following subsidiaries:

(X) AllianceBernstein L.P.

(13-3434400), an investment adviser registered under

Edgar Filing: PDL BIOPHARMA, INC. - Form SC 13G/A

Section 203 of the Investment Advisers Act of 1940.

- (X) AXA Equitable Life Insurance Company
(13-5570651), an insurance company and an investment
adviser registered under Section 203 of the Investment
Advisers Act of 1940.

Page 11 of 11 Pages

Item 8. Identification and Classification of Members of the Group.
N/A

Item 9. Notice of Dissolution of Group: N/A

Item 10. Certification:

By signing below I certify that to the best of my knowledge
and
belief, the securities referred to above were acquired in the
ordinary
course of business and were not acquired for the purpose of and
do not
have the effect of changing or influencing the control of the
issuer
of such securities and were not acquired in connection with or as
a
participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
Date: ,February 12, 2010 AXA FINANCIAL, INC.*

/s/ Alvin H. Fenichel

Alvin H. Fenichel
Senior Vice President
and Controller

*Pursuant to the Joint Filing Agreement with respect to Schedule 13G
attached hereto as Exhibit I, among AXA Financial, Inc., AXA Assurances
I.A.R.D Mutuelle, AXA Assurances Vie Mutuelle, and AXA, this statement
Schedule 13G is filed on behalf of each of them.